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Abstract
The formation of methylarsonous acid (MAsIII) and dimethylarsinous acid (DMAsIII) in the course
of inorganic arsenic (iAs) metabolism plays an important role in the adverse effects of chronic
exposure to iAs. High-performance liquid chromatography-inductively coupled plasma-mass
spectrometry (HPLC-ICP-MS) and hydride generation-cryotrapping-atomic absorption
spectrometry (HG-CT-AAS) have been frequently used for the analysis of MAsIII and DMAsIII in
biological samples. While HG-CT-AAS has consistently detected MAsIII and DMAsIII, HPLC-
ICP-MS analyses have provided inconsistent and contradictory results. This study compares the
capacities of both methods to detect and quantify MAsIII and DMAsIII in an in vitro methylation
system consisting of recombinant human arsenic (+3 oxidation state) methyltransferase (AS3MT),
S-adenosylmethionine as a methyl donor, a non-thiol reductant tris(2-carboxyethyl)phosphine, and
arsenite (iAsIII) or MAsIII as substrate. The results show that reversed-phase HPLC-ICP-MS can
identify and quantify MAsIII and DMAsIII in aqueous mixtures of biologically relevant arsenical
standards. However, HPLC separation of the in vitro methylation mixture resulted in significant
losses of MAsIII, and particularly DMAsIII with total arsenic recoveries below 25%. Further
analyses showed that MAsIII and DMAsIII bind to AS3MT or interact with other components of
the methylation mixture, forming complexes that do not elute from the column. Oxidation of the
mixture with H2O2 which converted trivalent arsenicals to their pentavalent analogs prior to HPLC
separation increased total arsenic recoveries to ~95%. In contrast, HG-CT-AAS analysis found
large quantities of methylated trivalent arsenicals in mixtures incubated with either iAsIII or
MAsIII and provided high (>72%) arsenic recoveries. These data suggest that an HPLC-based
analysis of biological samples can underestimate MAsIII and DMAsIII concentrations and that
controlling for arsenic species recovery is essential to avoid artifacts.
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Arsenic (As) is one of the most prevalent elements in the Earth’s crust. Inorganic As (iAs)
species, arsenite (iAsIII) and arsenate (iAsV) are common ground and surface water
contaminants.1 Millions of people worldwide who drink iAs-contaminated water are at risk
of developing cancer and non-cancerous diseases, including hypertension, peripheral
neuropathy or diabetes.2–5 However, the susceptibility to chronic iAs toxicity varies among
individuals and depends, in part, on the efficiency and pattern of iAs metabolism. Thus, the
analysis of iAs metabolites in biological matrices has become an essential tool for
population studies examining the inter-individual differences in responses to iAs exposure,
as well as for laboratory studies using animal or in vitro models for iAs toxicity and
metabolism.
Once ingested, iAs is enzymatically methylated by As (+3 oxidation state) methyltransferase
(AS3MT) in a sequence of S-adenosylmethionine-dependent reactions.6 Both tri- and
pentavalent methylated oxoarsenicals are generated in this pathway, including methylarsonic
acid (MAsV), methylarsonous acid (MAsIII), dimethylarsinic acid (DMAsV), and
dimethylarsinous acid (DMAsIII) with trimethylarsine oxide (TMAsVO) being the final
metabolite in some mammalian species.7–9 All these tri- and pentavalent oxoarsenicals have
been detected in human urine and in biological samples collected in laboratory
experiments.10–18 Recent studies have suggested that in addition to oxoarsenicals, a variety
of sulfur-containing As species (thioarsenicals) can be produced in the course of iAs
metabolism, possibly by intestinal bacteria or by reactions of oxoarsenicals with hydrogen
sulfide in tissues.19–21 To date, only one of these thioarsenicals, dimethylmonothioarsinic
acid (DMMTA), has been detected in urine of people exposed to iAs in drinking water.22, 23
A growing body of evidence suggests that among all known metabolites of iAs, the
methylated trivalent oxoarsenicals (MAsIII and DMAsIII) are the most biologically active
and toxic species.24–27
The methods used for speciation analysis of As in biological samples have been discussed in
detail in several recent reviews.12, 28–31 Most of these methods use high-performance liquid
chromatography (HPLC) for separation of As species and various spectrometric techniques,
including inductively coupled plasma-mass spectrometry (ICP-MS) for quantification of As
in the chromatographic fractions. An alternative approach uses hydride generation (HG) to
convert iAs and methylated As species in analyzed samples to gaseous arsine (AsH3) with
boiling point (b.p.) of −55°C and methyl-substituted arsines: methylarsine (CH3AsH2, b.p.
2°C), dimethylarsine ((CH3)2AsH, b.p. 36°C) and trimethylarsine ((CH3)3As, b.p. 52°C).
The generation of arsines in reaction with sodium borohydride is then followed by a
cryotrapping (CT) step and separation of arsines by their boiling points. The HG-CT
techniques typically use atomic absorption spectrometry (AAS), atomic fluorescence
spectrometry, or ICP-MS for the detection and quantification of As in the separated
arsines.12, 29 In general, the HPLC-based methods are highly specific and can identify a
wide spectrum of As species, including species that originate in foods and are not products
of iAs metabolism in human body, e.g., arsenobetaine (AsB), arsenocholine (AsC),32 or
arsenosugars.30 The HG-based techniques are characterized by low detection limits, but
have only limited specificity. A thorough method development and validation using
appropriate standards and optimized HG conditions are required for these methods to
reliably identify and quantify As species and to avoid artifacts associated with generation of
a single form of arsine from two or more As species present in the analyzed samples.
A variety of HPLC-ICP-MS techniques have been used for separation of iAs metabolites
and other As species in aqueous solutions and biological samples, mainly urine. Anion-
exchange HPLC has been shown in some studies to separate tri- and pentavalent metabolites
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of iAs and As species originating in seafood, including AsB and AsC.10, 30, 33–35 Other
studies used a combination of anion- and cation-exchange chromatography to achieve the
same goal.16 On the other hand, reversed-phase HPLC has successfully separated AsC and
the tri- and pentavalent metabolites of iAs, including MAsIII and DMAsIII with the use of a
single column,36–40 but could not fully resolve AsB.41 Notably, while some researchers
using HPLC for As speciation analysis found MAsIII and/or DMAsIII in biological samples,
including human urine,10, 16, 35, 36, 38–40, 42–45 others failed to detect these metabolites.28, 46
What causes these inconsistent results is unclear but the oxidation of MAsIII and DMAsIII in
aqueous solutions and in human urine18, 37,47 could play a major role. In addition, HPLC-
based analysis typically involves sample preparation (extraction, filtration, etc.) which could
produce oxidation state specific conversions and/or provide opportunities for unwanted
analyte interaction with the matrix, chemicals or surfaces inherent within the analysis
procedure.46 Because surprisingly many of the published studies did not employ oxidation
state specific procedural spikes or control for As-based mass balance to assess the impact of
these undesirable artifacts, it is difficult to determine whether a procedure element was
responsible for the analyte loss or conversion.
Unlike HPLC, the HG-CT-based methods, specifically HG-CT-AAS and HG-CT-ICP-MS,
have consistently detected MAsIII and DMAsIII in biological samples, including urine of
individuals exposed to iAs in drinking water,15, 18, 48, 49 tissues from mice exposed
chronically to iAs,17, 47 mammalian cells or tissue cultures treated in vitro with iAs,48, 50, 51
and in vitro systems in which iAs was methylated by recombinant rat or human
AS3MT.50, 52 However, because of a limited specificity of the HG-based techniques, results
of these analyses have often been questioned and the detection of DMAsIII has been viewed
by some as an artifact.28, 53 The present study was designed to address these concerns. This
study compares the capacities of previously described reversed-phase HPLC-ICP-MS37–40
and HG-CT-AAS52, 54 techniques to detect and quantify MAsIII and DMAsIII in an in vitro
system in which the methylated As metabolites are produced in reactions catalyzed by
recombinant human AS3MT and which, because of its simplicity, limits possible artifacts.
Results of this study suggest that analysis of biological samples by HPLC-based techniques
can underestimate MAsIII or DMAsIII content due to the formation of stable complexes
between these arsenicals and proteins or other endogenous substances and due to retention
of these complexes on the chromatographic column.
Experimental
Arsenicals
The following arsenicals were used for method optimization and calibration: iAsIII
(NaAsIIIO2) and iAsV (Na2HAsVO4), both >99% pure from Sigma-Aldrich (St. Louis, MO,
USA); MAsV (CH3AsVO(ONa)2) and DMAsV ((CH3)2AsVO(OH)), both >98% pure from
Chem Service (West Chester, PA); and custom-synthesized oxomethylarsine (CH3AsO,
MAsIIIO; 96% pure), iododimethylarsine ((CH3)2AsI, DMAsIIII; 96% pure), TMAsVO
(94.1% pure), AsC (99.6% pure), and AsB (99.9% pure), which were provided for this study
by Professor William Cullen (University of British Columbia, Canada). The identity and
purity of the custom synthesized arsenicals were determined by 1H-NMR and mass
spectrometry. DMMTA (92% pure) was synthesized in Dr. Creed’s laboratory as previously
described.55 In aqueous solutions, MAsIIIO and DMAsIIII form the corresponding MAsIII
and DMAsIII oxoanions.56 Stock solutions of the pentavalent arsenicals, DMMTA, AsC and
AsB were prepared in deionized water (electrical resistivity >5 MΩ·cm; further referred to as
“water”) and stored at −80°C. Stock solutions of the methylated trivalent arsenicals were
prepared in ice-cold water immediately before each experiment to limit oxidation.
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HG-CT-AAS—The speciation analysis of As by HG-CT-AAS was performed as previously
described.50, 54 The instrumentation, reagents and operating conditions are summarized in
Table 1. Briefly, the HG-CT-AAS system consisted of custom made HG and CT units
controlled by FIAS 400 flow injection accessory (Perkin-Elmer, Norwalk, CT) and coupled
with AAnalyst 800 spectrometer (Perkin-Elmer) that was equipped with a multiple
microflame quartz tube atomizer (multiatomizer).54 Arsine and the methyl-substituted
arsines from trivalent arsenicals (iAsIII, MAsIII and DMAsIII) and from TMAsVO were
generated directly in a buffered reaction mixture containing 0.75 M Tris (pH 6) and 1%
NaBH4 in 0.1 % KOH (all from Sigma-Aldrich). To generate arsines from both tri- and
pentavalent arsenicals (iAsIII+V, MAsIII+V and DMAsIII+V) at pH 6, standards or samples
were pre-reduced with 2% L-cysteine hydrochloride (EMD Chemicals Inc., Gibbstown, NJ)
for 1 hour prior to the HG step. Arsines were cryotrapped in a capillary U-tube filled with
Chromosorb WAW-DCMS 45/60 (15% OV-3) (Sigma-Aldrich) submerged in liquid N2,
and then separated by their boiling points upon heating prior to detection by the AA
spectrometer. Concentrations of iAsV, MAsV, and DMAsV were calculated as the
differences between species concentrations obtained for the cysteine-treated and untreated
sample aliquots.
HPLC-ICP-MS—The HPLC-ICP-MS analysis followed a previously described isocratic
reversed-phase HPLC protocol.39 The operating conditions are summarized in Table 1. The
Prodigy ODS(3) C18 column (150 × 4.6 mm, Phenomenex, Torrance, CA) was heated to
30°C and eluted with a mobile phase containing tetrabutylammonium hydroxide (TBAH)
(Acros Organic, Morris Plains, NJ), malonic acid (Sigma-Aldrich), and methanol (JT Baker
Chemical Co., Phillipsburg, NJ). Ultrapure nitric acid (Fisher Scientific Co., Fair Lawn, NJ)
was used to adjust pH of the mobile phase for optimal arsenical separation. The HPLC
column was connected with PTFE tubing to the nebulizer of a 7500cx ICP-MS (Agilent
Technologies, Palo Alto, CA).
In vitro methylation mixture
Recombinant human wild-type AS3MT which has methionine in position 287 was expressed
and purified as previously described.52 Methylated arsenicals were generated enzymatically
in a reaction mixture containing 100 mM TRIS-HCl buffer (pH 7.4, Mediatech, Inc.,
Manassas, VA), recombinant AS3MT, 1 mM tris(2-carboxyethyl)phosphine (TCEP, Sigma),
1 mM S-adenosylmethionine (SAM, Sigma), and iAsIII or MAsIII as substrates. The actual
measured concentrations of iAsIII or MAsIII in the mixtures prior to incubation were 0.93
μM (i.e., 10.4 As ng/150μL) and 1.09 μM (i.e., 12.2 ng As/150 μL), respectively. The
reaction mixtures with iAsIII contained 80 μg/mL of recombinant AS3MT and were
incubated for 2 hours at 37°C. MAsIII is methylated by AS3MT more efficiently than
iAsIII.52 Therefore, the mixtures containing MAsIII were incubated with 60 μg/mL of
AS3MT for only 40 minutes. The mixtures were then chilled on ice and split into aliquots
that were analyzed concurrently by HG-CT-AAS and HPLC-ICP-MS. Some of these
aliquots were treated with cysteine or 3% H2O2 (for 4 hours) prior to analysis as described
in Results and Discussion. Sums of As species detected by HG-CT-AAS or HPLC-ICP-MS
analyses were used to calculate As recovery as percentage of the known amount of As
present in the in vitro methylation mixture prior to incubation. Spikes of arsenical standards
into complete or incomplete reaction mixtures were used to assess interactions between the
components of the mixture and the metabolites of iAsIII or MAsIII and effects of these
interactions on results of the HG-CT-AAS and HPLC-ICP-MS analyses
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To examine binding of As species to AS3MT, the reaction mixtures with or without
recombinant AS3MT were spiked with iAsIII, MAsIII, or DMAsIII (1 μM each) and
incubated on ice for 5 minutes. After incubation, the reaction mixtures were filtered using
Nanosep Omega spin columns with 3 kDa cut-off (Pall Life Sciences, Ann Arbor, MI) at
4°C and 14,000 x g for 15 minutes. To ensure maximum As recovery, the columns were
washed with 100 μL of 100 mM TRIS-HCl buffer (pH 7.4) and centrifuged for an additional
15 minutes at 4°C. The filtrate and wash containing unbound arsenicals were analyzed by
HG-CT-AAS after cysteine pre-treatment.
Statistical Analysis
All statistical analyses were performed using the GraphPad Instat and GraphPad Prism
software packages (GraphPad Software Inc., San Diego, CA). Linear regression and
correlation analyses were employed to characterize the calibration curves. ANOVA
followed by Bonferroni’s multiple comparison posttest was used to determine significant
differences in As concentration between the analytical methods and the effects of protein




The method optimization focused on tri- and pentavalent As species that are substrates for
human AS3MT or are known to be produced in the course of iAs methylation by AS3MT,
including iAsIII, iAsV, MAsIII, MAsV, DMAsIII, DMAsV.8, 9 The following As species that
are not products of AS3MT-catalyzed methylation of iAs but are commonly found in human
urine were also included: TMAsVO, DMMTA, AsC and AsB.
HG-CT-AAS—The HG-CT-AAS technique has been previously optimized and used for
analysis of As species in biological systems as complex as tissue homogenates17, 47 or as
simple as in vitro methylation systems in which iAs was methylated by recombinant rat or
human AS3MT.50, 52 The oxidation state specific generation of arsine and methyl-
substituted arsines from tri- and pentavalent iAs and methylated arsenicals in a buffered
system at pH 6 has been described in details in our previous reports.50, 54 In absence of
cysteine pretreatment, arsines were generated almost exclusively from trivalent arsenicals
(iAsIII, MAsIII, and DMAsIII) and from TMAsVO. Only 3.5% of DMAsV and 11.7% of
DMMTA standards (2 ng As each) were converted to dimethylarsine under these
conditions.50 In the present study, 5.6 % of DMAsV standard (500 pg As) was converted to
dimethylarsine in the absence of cysteine (Figure 1A). Notably, DMMTA cannot be present
in the in vitro methylation system used in this study because the reaction mixture does not
contain H2S or other donors of sulfur needed for DMMTA formation. Thus, arsine and
methyl-substituted arsines generated from the in vitro methylation mixture can only
represent iAsIII, iAsV, MAsIII, MAsV, DMAsIII, DMAsV, or TMAsVO. Consistent with
previous reports,57, 58 no arsines were detected by HG-CT-AAS analysis of either cysteine-
treated or untreated aqueous solutions of AsC or AsB (data not shown).
HPLC-ICP-MS—The reversed-phase C18 column and mobile phases consisting of TBAH,
malonic acid, and methanol have been used by other laboratories for the HPLC-ICP-MS
analysis of As species in aqueous solutions, human urine, saliva or cells.38–40, 59 This
method was tested in the present study using a 150 × 4.6 mm C18 column heated to 30°C. A
nearly base-line separation of six oxoarsenicals (iAsIII, iAsV, MAsIII, MAsV, DMAsIII, and
DMAsV) and DMMTA was achieved with the mobile phase consisting of 4.7 mM TBAH, 2
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mM malonic acid, and 4% methanol at pH 5.85 and with a flow rate of 1.5 mL/min (Figure
1B). In this study, pH 5.6–5.8 or 5.9–6.0 resulted in an incomplete separation of iAsV,
DMAsIII, and DMMTA (data not shown). The optimized mobile phase was also used to
examine elution profiles of TMAsVO, AsC and AsB. The retention time for AsC was shorter
than those for all the other As species; however, TMAsVO, and AsB co-eluted with iAsIII
(Figure S1, Supplementary Data). The co-elution of TMAsVO and AsB with iAsIII did not
represent a problem for the current study because neither TMAsVO nor AsB are products of
the methylation of iAs by human AS3MT. However, without further optimization, this
HPLC technique could produce artifacts if used for analysis of biological samples that
contain all three As species, e.g., human urine.
Calibration
Calibration curves were prepared only for the tri- and pentavalent oxoarsenicals that are
products of As methylation by human AS3MT.
HG-CT-AAS—Aqueous solutions of the pentavalent As standards (iAsV, MAsV, and
DMAsV) pre-reduced with cysteine were used to generate 5-point calibration curves. The
calibration procedure, including validation using the trivalent As standards has been
described in our previous reports.50, 54 Slopes of the calibration curves are provided in Table
S1 (Supplementary Data). We have previously shown that the slopes of calibration curves
for As standards prepared in water and for As standards prepared in complex biological
matrices (e.g., cell lysates or tissue homogenates) do not significantly differ.17, 48, 50 Thus,
the calibration curves for As standards prepared in water were used in the present study for
quantification of As metabolites in the in vitro methylation mixtures analyzed by HG-CT-
AAS.
HPLC-ICP-MS—Six-point calibration curves were prepared using solutions of tri- and
pentavalent As standards in water or in the in vitro methylation mixture containing Tris-HCl
buffer, SAM and TCEP, but not AS3MT. Consistent with some of the previously published
data,37, 40 slopes of the calibration curves for individual As standards varied (Table S1,
Supplementary Data). Specifically, the calibration slopes for MAsIII and DMAsIII in either
solvent were lower than those for the other As standards, suggesting that these methylated
trivalent arsenicals are partially retained on the column. A lower calibration slope was also
found for iAsV standard prepared in the in vitro methylation mixture lacking AS3MT. Thus,
the calibration curves for As standards prepared in the mixture containing Tris-HCl buffer,
SAM and TCEP, but not AS3MT were used in the present study to quantify As metabolites
detected by HPLC-ICP-MS.
Limits of detection (LODs)
Standard deviations (SDs) of the integrated peak areas corresponding to the retention times
of As standards were determined for 10 injections of 500 μL of water or 2% cysteine in
water into the HG-CT-AAS system or 20 μl of water into the HPLC-ICP-MS system. These
injection volumes are consistent with the volumes of samples analyzed by HG-CT-AAS and
HPLC-ICP-MS in this study. The LOD value was calculated for each As species as: pg As
mL−1 = (3*SD)/(slope*injection volume) (Table S2, Supplementary Data). LOD values for
HG-CT-AAS ranged from 24 to 57 pg As mL−1; LODs for HPLC-ICP-MS were generally
higher, ranging from 31 pg As mL−1 for MAsIII to 295 pg As mL−1 for iAsV.
Speciation analysis of As in the in vitro methylation mixture
The in vitro mixtures were incubated with either iAsIII or MAsIII as described in
Experimental. Two aliquots from each reaction mixture were immediately and
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simultaneously analyzed by HG-CT-AAS and HPLC-ICP-MS. Here, one aliquot (20 μL of
the mixture) was diluted to 500 mL with ice-cold water and analyzed by HG-CT-AAS. The
other 20-μl aliquot was injected directly into the HPLC-ICP-MS system. Two additional
aliquots (20 μL each) were treated either with cysteine for determination of AsIII+V species
by HG-CT-AAS or with H2O2 for analysis of AsIII+V species by HPLC-ICP-MS.
Analysis of the reaction mixture incubated with iAsIII—Representative
chromatograms and amounts of As species detected in the mixture after incubation with
iAsIII are shown in Figure 2. HG-CT-AAS identified two methylated metabolites, DMAsIII
and DMAsV (Figure 2A), which on average accounted for 43% and 16% of As added as
iAsIII into the mixture prior to incubation; 13% of iAsIII remained unmethylated (Figure
2C). The average sum of As species detected by HG-CT-AAS in the mixtures treated with
cysteine was 7.5 ng, i.e., 72% of the added As (Figure 2D). In contrast, two major peaks
recorded by the direct HPLC-ICP-MS analysis represented DMAsV and iAsIII (Figure 2B)
and accounted for only 12% and 9.4% of the added As, respectively (Figure 2C). DMAsIII
was a minor metabolite (3% of the added As). Only 19–25% of the added As was recovered
by the direct HPLC-ICP-MS analysis (Figure 2D). However, As recovery by HPLC-ICP-MS
increased dramatically after oxidation of the reaction mixture with H2O2, reaching on
average 95%. Here, DMAsV was the major As species detected, representing on average 7.1
ng As, i.e., 68% of the added As. Notably, the amount of DMAsV detected in the oxidized
mixtures exceeded by 4.6 folds sums of DMAsIII + DMAsV found by the direct HPLC-ICP-
MS analysis, but was in a good agreement with the sum of DMAsIII + DMAsV detected by
HG-CT-AAS.
Analysis of the reaction mixture incubated with MAsIII—Results of this analysis are
summarized in Figure 3. The HG-CT-AAS analysis found DMAsIII to be the major product
of MAsIII methylation, accounting on average for 52% of the added As; DMAsV represented
10% of the added As. About 21.5% of the substrate remained unmethylated and was
partially oxidized during the incubation to MAsV (Figure 3A, C). The recovery of As in the
cysteine-treated mixtures was 83.4% (Figure 3D). In comparison, DMAsV was the only
major species detected by the direct HPLC-ICP-MS analysis, representing 16.7% of added
As. No DMAsIII and only traces of the unmethylated MAsIII were found. In the reaction
mixtures oxidized with H2O2, DMAsV and MAsV were the major species, accounting for
74% and 23% of added As. Here again, the total amounts of MAsV and DMAsV in the
oxidized mixtures analyzed by HPLC-ICP-MS compared well with the sums of MAsIII +
MAsV and DMAsIII + DMAsV detected by HG-CT-AAS. The average As recovery by
HPLC-ICP-MS was 19.3% and 99% for the reaction mixtures before and after oxidation
with H2O2.
Taken together, these results suggest that DMAsIII is the major product of iAsIII and MAsIII
methylation by recombinant AS3MT. However, the direct HPLC-ICP-MS analysis provides
very low As recoveries (19–25%) and underestimates DMAsIII yields because a major
portion of this metabolite either alone or in complexes with AS3MT protein or other
components of the reaction mixture is lost on the chromatographic column. The interactions
of DMAsIII with the components of the reaction mixture may also be responsible for the
incomplete As recoveries (72–83.4%) during the HG-CT-AAS analysis. Notably, the HPLC-
ICP-MS analysis detected DMAsIII also in the oxidized methylation mixture. This finding
suggests that a longer incubation or a higher concentration of H2O2 may be needed to
quantitatively release DMAsIII from its binding sites and/or to convert it into DMAsV.
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Interactions of AsIII species with the components of the methylation mixture
This and other laboratories have previously shown that rat and human AS3MT require a
reductant for activity.8, 52 Although the reductant function is not entirely clear, it has been
hypothesized that it is needed for maintenance or re-activation of the catalytically active
AS3MT cysteines. Both thiol and non thiol reductants have been used in the in vitro assay
systems for the AS3MT catalyzed methylation of arsenicals. However, trivalent arsenicals
are known to bind to thiol. Thus, we chose TCEP, a non-thiol reductant, for this study to
limit the formation of thiol-AsIII complexes which could interfere with As recovery or
speciation. To investigate the interactions of DMAsIII and other trivalent oxoarsenicals with
AS3MT, we compared HPLC profiles for the iAsIII, MAsIII and DMAsIII standards (0.5 uM
each) that were incubated for 5 minutes in the complete reaction mixture (1 mM TCEP and
1 mM SAM in 100 mM Tris-HCl buffer) or in the Tris-HCl buffer in the presence or
absence of recombinant AS3MT (60 μg/mL). The incubation was carried out at 0°C to
suppress the enzymatic activity of AS3MT. The presence of the recombinant protein in the
complete reaction mixture dramatically changed the HPLC profiles and recoveries for all
three arsenicals (Figure 4). Only 47% of iAsIII and 6% of MAsIII were recovered from the
mixtures containing AS3MT as compared to the mixtures that lacked the protein (Figure 4B,
C). However, presence of AS3MT had no significant effects on HPLC profiles and
recoveries of the iAsIII or MAsIII standards that were incubated in the Tris-HCl buffer
(Figure S2A, B, Supplementary Data), suggesting that the presence of SAM or TCEP
facilitates the interactions of these arsenicals with the enzyme. In contrast, DMAsIII was
detected only in the mixture with Tris-HCl buffer, but not in the complete reaction mixtures
incubated either in the presence or absence of AS3MT (Figure 4D). Incubation of DMAsIII
with AS3MT in the Tris-HCl buffer in absence of SAM and TCEP decreased the area of
DMAsIII to 21% (Figure S2C, Supplementary Data). Incubation of DMAsIII in the Tris-HCl
buffer with either 1 mM SAM or 1 mM TCEP in the absence of AS3MT also decreased the
DMAsIII signal, and thus recovery during the HPLC separation (Figure S2C, Supplementary
Data). These results suggest that, unlike iAsIII or MAsIII, DMAsIII interacts not only with
AS3MT, but also with SAM and TCEP, making a quantitative HPLC-ICP-MS analysis of
this metabolite in the complete reaction mixture practically impossible.
Binding of AsIII species to AS3MT
The interactions of As species with AS3MT were further examined using ultrafiltration.
Here, iAsIII, MAsIII, or DMAsIII (1 μM each) were incubated in the complete in vitro
reaction mixture in presence or absence of recombinant AS3MT (60 μg/mL) at 0°C for 5
minutes. After incubation, an aliquot of each reaction mixture was treated with cysteine and
analyzed by HG-CT-AAS for AsIII+V species. A second aliquot was ultrafiltered using a Pall
Omega 3k spin column with a 3 kDa cut-off filter membrane. The filtrate and wash (i.e., the
low-molecular weight fraction) were analyzed by HG-CT-AAS for AsIII+V species. Figure 5
summarizes results of the analyses of the unfiltered aliquots and the ultrafiltrates. The
amounts of arsenicals detected by HG-CT-AAS in the unfiltered aliquots of the mixtures
containing AS3MT were lower as compared to the unfiltered aliquots of mixtures that did
not contain the recombinant protein. However, this difference was statistically significant
only for mixtures incubated with MAsIII or DMAsIII (Figure 5B, C), suggesting that
interactions of these arsenicals with the recombinant protein limit the efficiency of hydride
generation. The HG-CT-AAS analysis of ultrafiltrates confirmed that significant amounts of
MAsIII or DMAsIII are bound to AS3MT. Specifically, the amounts of MAsIII or DMAsIII
were significantly lower (by 38 and 40%, respectively) in ultrafiltrates from the AS3MT-
containing mixtures as compared to the unfiltered AS3MT-containing mixtures. In contrast,
ultrafiltration had no significant effects on the amount of iAsIII suggesting that iAsIII binds
to AS3MT with lower affinity than the methylated trivalent species (Figure 5A). These
findings are consistent with results of a recent study by Marapakala and associates who
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showed that MAsIII binds faster than iAsIII to CmArsM, a bacterial orthologue of AS3MT
(binding of DMAsIII was not examined).60 Notably, the losses of MAsIII or DMAsIII after
ultrafiltration were not as high as those observed during the separation of the in vitro
methylation mixtures by reversed-phase HPLC (Figure 2 and 3), suggesting that that the
AS3MT-bound MAsIII or DMAsIII partially oxidized and detached from the recombinant
protein during the ultrafiltration or that small complexes of arsenicals with TCEP and SAM
which are not eluted from the HPLC column can pass through the filter.
AS3MT is a cysteine-rich protein.9 Some of its cysteine residues have been shown to play
the catalytic role in the process of iAs methylation,61–63 possibly providing binding sites for
the substrate or reaction intermediates. However, other cysteine-containing proteins and
endogenous low-molecular weight thiols, like glutathione have been shown to bind As.64–69
Results of the present study suggest that by binding trivalent arsenicals, these proteins and
thiols can interfere with quantitative speciation analysis of As by HPLC-based techniques.
These results also show that DMAsIII interacts not only with AS3MT, but also with other
components of the in vitro methylation mixture – SAM and TCEP. Thus, it is possible that
interactions with these or other compounds may interfere with DMAsIII analysis in
biological samples, including urine. To test this hypothesis, we compared HPLC-ICP-MS
profiles for DMAsIII spiked into an ice-cold TRIS-HCl buffer or human urine at final
concentration of 0.5 μM (Figure 6). Notably, the peak area for DMAsIII in urine represented
only 27% of the peak area in the buffer, suggesting that the urine matrix significantly
impairs the ability of HPLC-ICP-MS to detect DMAsIII and that calibrating for aqueous
standards when analyzing As species in urine could result in a substantial underestimation of
DMAsIII content.
Conclusions
Results of this study demonstrate that reversed phase HPLC-ICP-MS and HG-CT-AAS are
almost equally effective when used for analysis of tri- and pentavalent iAs, MAs and DMAs
in standard solutions prepared in DWI or TRIS-HCl buffer. However, when these techniques
are utilized for analysis of a simple biological system in which the methylated arsenicals are
generated in enzymatic reactions, HG-CT-AAS produces much better As recoveries (mass
balances) than does HPLC-ICP-MS. This difference in performance is not detector based but
rather is associated with losses of the methylated trivalent arsenicals during chromatographic
separation. Spiking of the reaction mixture with standards provides evidence that MAsIII and
DMAsIII interact with AS3MT and/or other components of the mixture to produce
complexes that do not elute from the chromatographic column. These findings are consistent
with results of Šlejkovec and associates who reported an on-column binding and losses of
As species during analyses using an ion-exchange HPLC-ICP-MS.46 The higher recoveries
associated with HG-CT-AAS indicate that either the MAsIII-complexes and DMAsIII-
complexes are unstable in the chemical environment associated with the HG step or the
complexes produce the same hydrides as do free MAsIII and DMAsIII. In either case, if
quantifying MAsIII or DMAsIII as a biomarker is an essential part of the study objectives
then the existing HG-CT-AAS technique provides far less negative bias as compared to the
existing HPLC-ICP-MS approach. This negative bias is not only present in the in-vitro
system used here to illustrate the problem but it should also be expected in other biological
matrices which provide binding sites for MAsIII and DMAsIII, including human urine. The
need to assess the losses of trivalent methylated arsenicals during HPLC-based analyses is
clearly demonstrated in this study by almost complete recoveries of As from the reaction
mixtures treated with H2O2. Thus, laboratories that do not attempt to quantify species
specific recoveries or quantify the chromatographic mass balance within the matrix are
choosing not to estimate a source of uncertainty that may undermine the reliability and
utility of the data set.
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The separation and detection of As standards by HG-CT-AAS (A) and by optimized HPLC-
ICP-MS (B). For HG-CT-AAS, a mixture of three pentavalent oxoarsenicals (500 pg As
each) in 500 μL of water was analyzed directly (−Cys) or after reduction with 2% cysteine
(+Cys); the blank containing only water and 2% cysteine (Cys blank) is also shown. For
HPLC-ICP-MS, a mixture of six tri- and pentavalent oxoarsenicals and DMMTA (250 pg
As each) was injected in 20 μL of water. The HPLC-ICP-MS and HG-CT-AAS operating
conditions are described in Table 1.
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Analyses of the complete in vitro methylation mixtures containing recombinant AS3MT (80
μg/mL) incubated with iAsIII (10.4 ng) for 2 hours at 37°C. Representative HG-CT-AAS
(A) and HPLC-ICP-MS (B) chromatograms and amounts of As species detected (C) are
shown. The recovery of As by either method is expressed in ng As and as percentage of the
amount of As added into the reaction mixture prior to incubation (D). The mixtures were
analyzed by HPLC-ICP-MS directly (HPLC direct) or after oxidation with 3% H2O2 (HPLC
oxidized). HG-CT-AAS analysis was performed directly and after 2% cysteine pretreatment
to measure AsIII and AsIII+V species, respectively. Pentavalent As species were calculated as
the difference between these two analyses. Values are expressed as mean +SD for 4 separate
reaction mixtures.
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Analyses of the complete in vitro methylation mixtures containing recombinant AS3MT (60
μg/mL) incubated with MAsIII (12.2 ng) for 40 min at 37°C. Representative HG-CT-AAS
(A) and HPLC-ICP-MS (B) chromatograms and amounts of As species detected (C) are
shown. The recovery of As by either method is expressed in ng As and as percentage of the
amount of As added into the reaction mixture prior to incubation (D). The mixtures were
analyzed by HPLC-ICP-MS directly (HPLC direct) or after oxidation with 3% H2O2 (HPLC
oxidized). HG-CT-AAS analysis was performed directly and after 2% cysteine pretreatment
to measure AsIII and AsIII+V species, respectively. Pentavalent As species were calculated as
the difference between these two analyses. Values are expressed as mean +SD for 4 separate
reaction mixtures.
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The HPLC-ICP-MS profiles for trivalent arsenical standards spiked into the complete in
vitro methylation mixture (1 mM TCEP, 1 mM SAM in 100 mM TRIS-HCl buffer, pH 7.4)
in absence (—) or presence (---) of recombinant AS3MT (60 μg/mL). Representative
chromatograms for the methylation mixtures without As standards (A) and for the mixtures
incubated at 0°C for 5 minutes with 0.5 μM iAsIII (B), MAsIII (C), or DMAsIII (D) are
shown. In panel D, 0.5 μM DMAsIII in TRIS-HCl buffer (pH 7.4) ( ) is also shown.
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The amounts of trivalent arsenical standards in the complete reaction mixture before and
after ultrafiltration. The mixture (1 mM TCEP, 1 mM SAM in 100 mM TRIS-HCl buffer,
pH 7.4) was incubated at 0°C for 5 minutes with 1 μM iAsIII (A), MAsIII (B), or DMAsIII
(C) in presence or absence of recombinant AS3MT (60 μg/mL). The AsIII+V species were
analyzed by HG-CT-AAS in the mixtures before and after ultrafiltration using a 3 kDa
cutoff membrane. Values are expressed as mean +SD for 3 separate mixtures. The effect of
AS3MT protein (a, b) and of ultrafiltration (#) on the recovery of As were examined. Values
labeled with the same letter or symbol are significantly different (p<0.05).
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The HPLC-ICP-MS profiles for 0.5 μM DMAsIII standard spiked into 100 mM TRIS-HCl
buffer (pH 7.4) or into human urine from an unexposed subject.
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Table 1
HG-CT-AAS and HPLC-ICP-MS operating conditions
HG-CT Perkin-Elmer FIAS 400
Sample volume 500 μL
Buffer 0.75 M TRIS-HCl (pH 6.0)
Reducing agent 1% NaBH4 in 0.1% KOH
Carrier gases He (75 ml/min); H2 (15 ml/min)
Column packing Chromosorb WAW-DCMS 45/60 (15% OV-3)
Column heating Ni80/Cr20 wire, 15 Ω
AAS Perkin-Elmer AAnalyst 800
Lamp As electrodeless discharge (390 mA)
Wavelength 193.7 nm
Slit width 0.7 nm
Atomizer Multiatomizer (900°C)
Outer gas Air (35 ml/min)
HPLC Agilent 1260 Infinity Series
Column Phenomenex Prodigy 3μ ODS(3) 100A, 150×4.60 mm
Temperature 30 °C
Mobile phase 4.7 mM tetrabutylammonium hydroxide + 2 mM malonic acid + 4% methanol (pH 5.85)
Flow rate 1.5 mL/min
Injection volume 20 μL
ICP-MS Agilent 7500cx Series
Masses 75 (As), 77 (ArCl)
Integration time 0.1 s
RF power 1550 W
Skimmer cone Ni
Spray chamber Double-pass Scott-type
Sample depth 8 mm
S/C temperature 2 °C
Plasma gas (Ar) 15 L/min
Carrier gas (Ar) 0.95 L/min
Make-up gas (Ar) 0.25 L/min
Cell gas (He) 4.0 L/min
Nebulizer Micromist
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